Deepali Sen, MD
Rheumatology · Saint Louis, MONPI 1235459504
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $493 of the $582 with a category attached, or 84.7%. 6 manufacturers reported payments, led by AbbVie at 52.4% of the total. Reporting peaked in 2023 at $188 and has fallen 84.2% since, to $30 in 2025. That places this record below the midpoint for rheumatology clinicians in MO, where the typical reported total is $1,657.
Across 37 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- AstraZeneca$107
- E.r. Squibb & Sons, L.L.C.$89
- Pfizer$46
- GSK$18
- Amgen$17
Across 1 payment — averaging $11,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$12K
What the payments were for
- Food & beverage$49385%
- Education$8915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $305 |
| AstraZeneca | 1 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $89 |
| Pfizer | 3 | $46 |
| GSK | 1 | $18 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$107
How this compares
$582 in reported general payments places this provider in the 25th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 31 | $230,011 |
| Xeljanz XrTofacitinib Citrate | 34 | $222,957 |
| Humira(Cf)Adalimumab | 14 | $177,377 |
| XeljanzTofacitinib Citrate | 22 | $136,660 |
| Cosentyx Sensoready PenSecukinumab | 15 | $121,915 |
| Enbrel MiniEtanercept | 13 | $97,909 |
| Orencia ClickjectAbatacept | 11 | $70,627 |
| BenlystaBelimumab | 15 | $68,564 |
| Hydroxychloroquine Sulfate | 399 | $13,365 |
| Mycophenolate Mofetil | 114 | $8,828 |
| Leflunomide | 201 | $8,431 |
| MethotrexateMethotrexate Sodium | 299 | $5,094 |
| Gabapentin | 88 | $1,543 |
| Azathioprine | 76 | $1,470 |
| Colchicine | 44 | $1,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $305 | $177,37714 claims |
| PfizerXeljanz | $46 | $136,66022 claims |
| GSKBenlysta | $18 | $68,56415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Saint Louis
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Sona KamatSaint Louis$268K
- Richard BrasingtonSaint Louis$100K
- Akgun InceSaint Louis$45K
- Joseph StauberSaint Louis$37K
- Alissa ChandlerSaint Louis$37K
- Chad RonholmSaint Louis$27K
- Sandra HoffmannSaint Louis$23K
- John BuddSaint Louis$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.